Immunocore Holdings PLC
IMCR
Detailliertes Diagramm anzeigen
35.200USD
+0.200+0.57%
Handelsschluss 11/11, 16:00（ET）Kurse um 15 Minuten verzögert
1.75BMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+0.57%
5 Tage
+10.31%
1 Monat
+8.64%
6 Monate
+23.94%
Seit Jahresbeginn
+19.32%
1 Jahr
+1.62%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Immunocore Holdings PLC
Währung: USD Aktualisiert: 2025-11-11Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ sehr gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer durchschnittlichen Aktienmarktperformance zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Immunocore Holdings PLC Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
19
Analysten
Kaufen
Aktuelles Rating
65.765
Kursziel
+87.90%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Immunocore Holdings PLC Highlights
HöhepunkteRisiko
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=77.91%)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=-60.29)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=49.40M, string=12.11%)
institutional_hold%!(EXTRA string=Steven Cohen)
institutional_hold_desc%!(EXTRA string=Steven Cohen, string=820.42K)
Immunocore Holdings PLC Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Immunocore Holdings PLC Informationen
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
BörsenkürzelIMCR
UnternehmenImmunocore Holdings PLC
CEODr. Bahija Jallal, Ph.D.
Websitehttps://www.immunocore.com/
Verwandte Finanzinstrumente
+2.27%
+2.88%
+2.95%
+1.84%
+2.59%
+4.84%
+4.57%
+6.99%
+3.73%
+4.59%
+2.03%
+1.90%
-0.34%
+3.09%
+2.22%
+2.93%
0.00%
+3.03%
+2.32%
+2.28%Beliebte Symbole
